Brokerages Set Tcr2 Therapeutics Inc (TCRR) PT at $30.75

Shares of Tcr2 Therapeutics Inc (NASDAQ:TCRR) have received an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $30.75.

TCRR has been the subject of a number of recent analyst reports. BMO Capital Markets initiated coverage on Tcr2 Therapeutics in a report on Monday, March 11th. They set an “outperform” rating and a $37.00 price target for the company. Svb Leerink initiated coverage on Tcr2 Therapeutics in a report on Monday, March 11th. They set an “outperform” rating and a $27.00 price target for the company. Leerink Swann initiated coverage on Tcr2 Therapeutics in a report on Monday, March 11th. They set an “outperform” rating for the company. Wedbush initiated coverage on Tcr2 Therapeutics in a report on Monday, March 11th. They set an “outperform” rating and a $28.00 price target for the company. They noted that the move was a valuation call. Finally, Jefferies Financial Group initiated coverage on Tcr2 Therapeutics in a report on Monday, March 11th. They set a “buy” rating and a $31.00 price target for the company.

In other news, major shareholder Upnorth Investment Ltd bought 200,000 shares of Tcr2 Therapeutics stock in a transaction dated Tuesday, February 19th. The stock was acquired at an average cost of $15.00 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Morana Jovan-Embiricos bought 666,667 shares of Tcr2 Therapeutics stock in a transaction dated Tuesday, February 19th. The stock was purchased at an average cost of $15.00 per share, with a total value of $10,000,005.00. The disclosure for this purchase can be found here.

Institutional investors have recently bought and sold shares of the company. Dean Capital Investments Management LLC purchased a new stake in shares of Tcr2 Therapeutics in the 1st quarter valued at about $694,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Tcr2 Therapeutics in the 1st quarter valued at about $458,000. Hillhouse Capital Management LTD. purchased a new stake in shares of Tcr2 Therapeutics in the 1st quarter valued at about $5,628,000. Oxford Asset Management LLP purchased a new stake in shares of Tcr2 Therapeutics in the 1st quarter valued at about $301,000. Finally, ArrowMark Colorado Holdings LLC purchased a new stake in shares of Tcr2 Therapeutics in the 1st quarter valued at about $8,204,000. 1.04% of the stock is owned by institutional investors and hedge funds.

NASDAQ TCRR traded down $0.75 during trading on Tuesday, reaching $14.08. 13,438 shares of the company’s stock were exchanged, compared to its average volume of 19,304. The company has a market capitalization of $337.08 million and a price-to-earnings ratio of -0.14. Tcr2 Therapeutics has a 1 year low of $13.87 and a 1 year high of $25.47.

Tcr2 Therapeutics (NASDAQ:TCRR) last announced its quarterly earnings results on Monday, May 13th. The company reported ($4.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($4.47). Equities analysts anticipate that Tcr2 Therapeutics will post -6.08 earnings per share for the current year.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Featured Story: Stock Split

Analyst Recommendations for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.